### Citation

### As Published
http://dx.doi.org/10.1016/j.celrep.2013.03.019

### Publisher
Elsevier

### Version
Final published version

### Accessed
Sun Dec 30 16:19:22 EST 2018

### Citable Link
http://hdl.handle.net/1721.1/90308

### Terms of Use
Creative Commons Attribution

### Detailed Terms
http://creativecommons.org/licenses/by-nc-nd/3.0/
SIRT1 Suppresses the Epithelial-to-Mesenchymal Transition in Cancer Metastasis and Organ Fibrosis

Petra Simic, Eric O. Williams, Eric L. Bell, Jing Jing Gong, Michael Bonkowski, and Leonard Guarente

1Glenn Laboratory for the Science of Aging and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
Correspondence: leng@mit.edu
http://dx.doi.org/10.1016/j.celrep.2013.03.019

SUMMARY

The epithelial-to-mesenchymal transition (EMT) is important for the development of cancer metastases and organ fibrosis, conditions prevalent in aging. Because sirtuins affect the pathology of aging, we tested the effect of SirT1 on EMT. Reduced SIRT1 levels in HMLER breast cancer cells led to increased metastases in nude mice, and the loss of SIRT1 in kidney tubular epithelial cells exacerbated injury-induced kidney fibrosis. SIRT1 reduces EMT in cancer and fibrosis by deacetylating Smad4 and repressing the effect of TGF-β signaling on MMP7, a Smad4 target gene. Consequently, less E-cadherin is cleaved from the cell surface and β-catenin remains bound to E-cadherin at the cell-cell junctions. Our findings suggest that the SIRT1/Smad4/β-catenin axis may be a target for diseases driven by EMT.

INTRODUCTION

The epithelial-to-mesenchymal transition (EMT) is a process in which epithelial cells lose cell-adhesive properties, repress E-cadherin expression, and increase mesenchymal gene expression and cell motility. It is essential for three distinct biological processes: embryogenesis, organ fibrosis, and cancer metastases (Kalluri and Weinberg, 2009).

In cancer, EMT enables carcinoma cells to acquire cellular traits associated with high-grade malignancy and metastasis (Brabletz et al., 2005; Singh and Settleman, 2010). Some of the epithelial cells that enter EMT acquire the properties of stem cells (Mani et al., 2008; Morel et al., 2008). Importantly, this includes the potential for self-renewal, which may facilitate the formation of secondary tumors by disseminating cancer cells. EMT-derived migratory cancer cells establish secondary colonies at distant sites that resemble, at the histopathological level, the primary tumor from which they arose, suggesting that metastasizing cancer cells shed their mesenchymal phenotype via a mesenchymal to epithelial transition (MET) during the colonization process (Kalluri and Weinberg, 2009; Yao et al., 2011).

EMT was also proposed to occur in fibrosis of kidney, liver, heart, lung, and intestine (Potenta et al., 2008; Zeisberg et al., 2007; Kim et al., 2006). However, recent studies raised serious doubts about the existence of EMT in kidney fibrosis (Humphreys et al., 2010; Li et al., 2010b).

EMT in cancer progression and organ fibrosis is associated with aging (Mani et al., 2008; Chaturvedi and Hass, 2011; Pannarale et al., 2010). Indeed, aging is one of the single most important risk factors associated with cancer with nearly 65% of cancers occurring in patients ≥65 years old (Ertel et al., 2012). Similarly, fibrosis is a hallmark of pathogenesis associated with aging in many organs (Abrass et al., 1995).

Sirtuins are highly conserved nicotinamide-adenine-dinucleotide -dependent deacetylases that were shown to regulate lifespan in lower organisms (Tissenbaum and Guarente, 2001; Viswanathan and Guarente, 2011) and affect diseases of aging in mammals, such as diabetes, inflammation, and neurodegenerative diseases (Donmez and Guarente, 2010). The Sir2 ortholog SIRT1 is known to deacetylate transcription factors that govern pathways important for aging and diseases (Imai et al., 2000; Guarente, 2011).

Furthermore, calorie restriction protects against breast cancer (Nogueira et al., 2012), as well as against fibrotic kidney failure (Tapp et al., 1989) via SIRT1 (Kume et al., 2010). Indeed, there is a strong link between sirtuins and many of the effects of calorie restriction (Lin et al., 2000; Guarente and Picard, 2005), hinting at a possible relationship between mammalian SIRT1 and EMT. The role of SIRT1 in cancer has been shown in several studies to be cell type dependent and complex (see Discussion). Here, we investigated the role of SIRT1 in EMT in cancer metastasis and fibrosis. For this purpose, we analyzed the metastatic potential of breast cancer cells with or without SIRT1 after implantation into nude mice. We also probed the role of SIRT1 in long-term effects of ischemia reperfusion on kidney fibrosis in mice with varying levels of SIRT1 expression in tubular epithelial cells. After observing significant effects in these systems, we demonstrated that SIRT1 restrains the transforming-growth-factor (TGF)-β-signaling pathway, which is known to drive EMT. Our findings cast light on links between sirtuins and disease states abetted by the EMT.

RESULTS

Decrease in SIRT1 Level Promotes Breast Cancer Metastases via EMT

We initially tested the effect of SIRT1 on EMT in breast cancer cells. HMLER cells are primary human mammary epithelial cells (HMECs), which express the telomerase catalytic subunit, SV40
large T and small t antigens (HMLE cells), and an oncogenic allele of H-Ras, H-RasV12 (Elenbaas et al., 2001). These cells are tumorigenic when injected subcutaneously or into the mammary glands of immunocompromised mice but have very low metastatic potential (Elenbaas et al., 2001, Ince et al., 2007). Treatment of HMLE cells with TGF-β led to transition of epithelial to mesenchymal cells as shown by a reduction of E-cadherin (epithelial marker) and an increase in vimentin (mesenchymal marker, Figure 1A). Overexpression of SIRT1 reduced EMT, while repression of SIRT1 by small interfering RNA (siRNA) increased EMT of HMLE cells in these assays (Figures 1A and S1A). Similar albeit less dramatic results were repeated in another breast cancer line MDA-MB231 (Figure S1B).

HMLE cells were stably transfected with the control vector or knockdown construct for SIRT1 (SIRT1 KD) (Figure S1C). A group of 15 mice were implanted with HMLE cells in the mammary fat pad of nude mice (seven with control and eight with HMLE SIRT1 KD cells), where they both grew mammary tumors similar in size (Figure 1B). However, nude mice with SIRT1 KD tumors had significantly reduced survival, with only 50% of mice surviving until 8 weeks following the implantation of tumor cells as compared to 86% survival in mice with wild-type tumors (Figure 1C). In a second trial, 17 mice (eight control and nine HMLE SIRT1 KD implanted cells) showed a similar pattern, 56% survival in mice with SIRT1 KD tumors and 100% survival in mice with wild-type tumors 7.5 weeks following tumor implantation (Figure 1D). Upon dissection, it was revealed in the first trial that seven out of eight mice with SIRT1 KD tumors had multiple metastases, in liver (50% of mice), lung (38% of mice), spleen (13% of mice), and bone (13% of mice), while only one mouse out of seven had a single liver metastasis after implantation of wild-type tumor cells (Figure 1E). Metastasis burden analysis showed a substantial portion of liver, lung, and spleen surface covered with metastases in mice bearing SIRT1 KD tumors (Figures 1F and 1G). Histology of these organs showed the purely differentiated phenotype characteristic of HMLE cells (Figure 1H). The origin of metastasis was additionally confirmed to be HMLE cells with immunohistochemical staining of large T antigen, used for transformation of HMEC to HMLE cells (Figure 1I). In the second experiment, seven out of nine mice with SIRT1 KD tumors had metastases, 56% in lung and 33% in liver (Figure 1J), with 31%–48% of organs covered with metastases (Figure 1K). The HMLE origin of metastases was confirmed by immunohistochemical staining of large T antigen (Figure 1L) and scoring the GFP marker present in these cells (Figure S1D). None of the mice with HMLE wild-type tumors developed metastases in this experiment (Figures 1J and 1K). SIRT1 levels in the knockdown remained low in metastases as well as in primary tumors (Figure S1E). To determine migratory and invasive abilities of cells more directly, we used Boyden chamber assays. Whereas control cells were minimally motile and invasive, SIRT1 KD cells showed a significant increase in both motility and invasiveness through Matrigel-coated membranes (Figures 1M and 1N). Taken together, these results indicate that knocking down SIRT1 in breast cancer cells promotes EMT, cancer cell invasiveness, metastases, and increased mortality of nude mice.

To further confirm the effect of SIRT1 on breast cancer metastases, we performed meta-analysis of SIRT1 expression in all breast cancer clinical studies in the Oncomine human cancer gene expression database, which includes 12 trials with 143 control and 1,181 breast cancer tissues (http://www.oncomine.com). We used the cutoff value of p = 0.01 for significance of any change in SIRT1 expression in any direction. Six out of 12 studies (nine out of 35 total comparisons) showed a significant change in SIRT1 expression, and strikingly SIRT1 was downregulated in all nine comparisons (fold change −1.216 to −4.822; Figure 1O; Table S1).

Loss of SIRT1 Leads to Kidney Fibrosis via EMT

We next wished to test a possible role of SIRT1 in EMT in a completely different context from tumor metastasis by using...
Figure 2. The Role of SIRT1 in EMT of Kidney Epithelial Cells and Kidney Fibrosis In Vivo
(A) Immunofluorescent staining of HK-2 cells with E-cadherin, α-smooth muscle actin (α-SMA), and collagen type I 48 hr following the treatment with TGF-β 5 ng/ml (63x magnification, DAPI staining of nuclei). Numbers in the right bottom corners of images represent percentage of E-cadherin, α-SMA, or collagen-type-I-positive cells over total number of cells per slide (n = 3 slides per group), shown as average ± SD, *p < 0.05, ANOVA Dunnett test versus Ctrl treated with TGF-β; T1Tg, HK-2 cells overexpressing SIRT1; siT1, HK-2 cells with knockdown for SIRT1; Ctrl, control HK-2 cells.
(B) Changes of serum creatinine over time following AKI (n = 12 for each time point).
(C) Survival following the AKI, *p ≤ 0.05 versus Ctrl KO, #p ≤ 0.05 versus Ctrl Tg, log-rank test.
(D) Blood urea nitrogen (BUN) values over time (n = 12 for each time point).
(E) Masson’s trichrome staining showing mesenchymal tissue in blue and α-SMA immunofluorescent staining for myofibroblasts in red (magnification 20x, n = 6 per group).
(F) Interstitial fibrosis score of Masson’s trichrome-stained kidney sections at 6 weeks following the AKI (n = 6 per group).
(G) Collagen content in kidneys 6 weeks following the AKI measured by Sircol assay (n = 6 per group).
(H) Masson’s trichrome staining of kidneys after 4 days of treatment with TGF-β 100 μg/kg/day intravenously (magnification 5x).
(I) Interstitial fibrosis score of Masson’s trichrome-stained kidney slides from (H).
(J) Collagen content in kidneys after 4 days of treatment with TGF-β 100 μg/kg/day intravenously, as determined by Sircol collagen assay. *Significantly different from Ctrl KO, #significantly different from Ctrl Tg, ANOVA Dunnett test, p ≤ 0.05. Error bars represent SD. KSTG, kidney-specific transgenic mice; Ctrl Tg, control for KSTG; KSKO, kidney-specific knockout mice; Ctrl KO, control for KSKO mice.

(legend continued on next page)
kidney epithelial cells and a kidney injury model in mice expressing reduced or elevated levels of SIRT1 (Figure S2A).

Treatment of kidney epithelial HK-2 cells with TGF-β or aristrocholic acid, to mimic kidney injury, gave rise to cells with mesenchymal phenotypes, as shown by an increase in cells positive for α-smooth muscle actin (α-SMA) and collagen type I (markers for mesenchymal cells) and a decrease in cells positive for E-cadherin, an epithelial marker (Figures 2A and S2B). Overexpression of SIRT1 in epithelial HK-2 cells led to a repression of EMT, as seen by a reduction in α-SMA and collagen-positive cells. Moreover, preservation of the epithelial phenotype was confirmed by the continued expression of E-cadherin after the treatments with TGF-β or aristrocholic acid (Figures 2A and S2B). Conversely, loss of SIRT1 by siRNA in HK-2 kidney epithelial cells increased the EMT, as assessed by an increase in α-SMA and collagen-positive cells and a decrease in E-cadherin-positive cells (Figures 2A and S2B).

To test the effect of SIRT1 on kidney function in vivo, we studied the acute kidney injury (AKI) model of ischemia reperfusion in kidney-specific knockout mice (KSKO) and kidney-specific transgenic mice (KSTG) mice. KSKO mice eliminate SIRT1 from kidney collective tubular epithelial cells, while KSTG increase SIRT1 expression in these same cells (Figures S2C–S2E). At the baseline, KSTG and KSKO had comparable body weight and levels of serum electrolytes (Figures S2F and S2G). Serum creatinine values, representing kidney function, were increased in KSKO mice before the AKI (Figure 2B), suggesting the requirement of SIRT1 for maintenance of tubular epithelial function even in the absence of injury. After clamping the renal arteries to induce injury, the increase of the serum creatinine was much more pronounced in the absence of SIRT1 from kidney tubules (Figure 2B). There was an improvement in creatinine values in KSKO mice on day 4 following the AKI, since the mice with the worst glomerular function had died by that time (Figure 2C). KSTG showed better kidney function parameters with significantly lower creatinine values as compared to the control animals. Blood urea nitrogen (BUN) paralleled serum creatinine measurements (Figure 2D). Most importantly, overexpression of SIRT1 in kidney tubules protected animals from dying after AKI, while deletion exacerbated mortality (Figure 2C). Histological examination of the injured kidneys demonstrated destruction of the tubular basement membrane and disorientation of epithelial tubular cells following the AKI. These phenotypes were significantly more pronounced in KSKO and reduced in KSTG mice (Figures S2H and S2I).

Since aging impedes the recovery from AKI and predisposes to irreversible damage of kidneys (Abrass et al., 1995), we investigated the effect of SIRT1 on fibrosis in kidneys without the injury and on progression of AKI to tubulointerstitial fibrosis and development of chronic kidney damage (CKD) by following the KSKO and KSTG mice for 6 weeks after the AKI. At baseline, KSKO mice had a minimal increase in kidney fibrosis (Figure S2J). After the AKI, KSKO mice had significantly worse kidney function as detected by the increased serum creatinine (Figure S2K) and BUN (Figure S2L), more kidney fibrosis (Figure 2F) as confirmed by Masson’s trichrome staining for connective tissue and α-SMA staining for myofibroblasts (Figure 2E) and increased kidney collagen content (Figure 2G). In contrast, KSTG showed improvement compared to the control mice subjected to kidney injury. In summary, the elimination of SIRT1 predisposes kidneys to fibrosis and progression from AKI to CKD, while overexpression of SIRT1 in kidney tubules improves the recovery after the AKI and slows the progression toward CKD.

Our findings above suggest that SIRT1 represses kidney fibrosis. Since it is known that the TGF-β pathway induces fibrosis (Ledbetter et al., 2000), we tested whether SIRT1 repression of TGF-β was sufficient to explain the observed repression in fibrosis. We treated wild-type, KSKO, and KSTG mice with 100 μg/kg of TGF-β intravenously for 4 days. In mice treated with TGF-β, we recapitulated the effects of SIRT1 seen after AKI. Namely, KSTG mice showed less fibrosis on histology (Figures 2H and 2I) and less collagen (Figure 2J) in kidney tissues, and KSKO mice showed more fibrosis and collagen after the treatment with TGF-β. These results suggest that SIRT1 represses kidney fibrosis by repressing the TGF-β pathway.

To address whether EMT was likely to be involved in fibrosis in wild-type or KSKO kidneys, we FACS sorted α-SMA-positive cells after treatment with TGF-β to cause fibrosis, and found, as expected, 4.8-fold more positive (fibrotic) cells in kidneys of KSKO mice (Figure 2K). Since cre-recombinase expression in KSKO mice is driven by the kidney epithelial collecting tubule-specific Hoxb7cre promoter (Yu et al., 2002), we tested for EMT by FACS sorting the α-SMA-positive cells and testing for cre expression. Consistent with recent reports (Humphreys et al., 2010), almost none of sorted α-SMA-positive cells had cre recombinase (0.02%) in SIRT1+/− mice expressing cre, after the TGF-β treatment. In striking contrast, 35.7% of α-SMA-positive cells in KSKO mice treated with TGF-β expressed cre recombinase (Figure 2L). Quantitative RT-PCR also demonstrated vastly higher cre expression in α-SMA-positive cells of KSKO compared to wild-type (Figure 2M). These findings suggest that EMT is not the mechanism of kidney fibrosis in control animals as recently reported (Humphreys et al., 2010). However, EMT is induced at a very high frequency in fibrotic kidney tissue in the absence of SIRT1.

**SIRT1 Deacetylates Smad4 and Represses the Activity of TGF-β Pathway on MMP7**

Since MMP7 has been associated with aging and fibrosis in kidneys (Chen et al., 2007), we determined the levels of this protein in the various mice after AKI. In KSTG mice, there was significantly less expression of MMP7 after AKI, while the expression...
Figure 3. SIRT1 Represses the Activity of TGF-β Pathway on MMP7

(A) MMP7 fold change detected by quantitative RT-PCR in kidneys 6 days following the AKI (n = 6 per group).

(B) Immunohistochemistry showing localization of MMP7 around tubules in kidneys 6 days following AKI (Vecta-stain, 5× magnification).

(C) Immunofluorescent staining for collagen type IV for tubular basement membrane and DAPI for nuclei in kidney sections 6 days following AKI (20× magnification). Numbers in the bottom-right corners of images represent percentage of collagen-IV-positive green area over total area (n = 3 slides per group), shown as average ± SD. Arrows depict destruction of collagen IV in the basement membrane.

(D) Quantitative RT-PCR expression of TGF-β I and some of TGF-β target genes—Pitx2, Lefty and Afp—in kidneys 6 days following AKI.

(E) Luciferase activity of MMP7 promoter (–660 to –280) in wild-type, SIRT1+/− and SIRT1-overexpressing MEFs treated with TGF-β (2 ng/ml for 48 hr). Left, vector control; right, shRNA Smad4.

(F) MMP7 immunofluorescent staining of kidney epithelial tubular HK-2 cells treated with TGF-β 5 ng/ml for 48 hr (63× magnification, DAPI staining of nuclei). Bar graph is quantification of MMP7 immunofluorescence intensity by ImageJ. In each of the four groups, three to four different fields were analyzed. *Significantly different from Ctrl, ANOVA Dunnett test, p < 0.05. Error bars represent SD.

(G) Chromatin-immunoprecipitation on kidneys 6 days following the AKI with anti-Smad4 antibody or IgG. Different activity regions of the MMP7 promoter are tested by quantitative RT-PCR using the appropriate primers (Table S2).
of MMP7 was increased 5.7-fold in KSKO kidney (Figure 3A). Immunohistochemistry revealed increased levels of MMP7 protein at the basement membrane of collecting tubules in KSKO mice (Figure 3B). The increment of MMP7 in KSKO kidneys correlated with increased destruction of collagen IV, a basement membrane-specific target of MMP7, as shown by immunofluorescent staining (Figure 3C). Conversely, there was less MMP7 protein and less basal membrane destruction in kidneys from KSTG mice (Figures 3B and 3C). There were no significant changes in the expression of MMP2 or MMP9 (Figure S3A).

Since TGF-β signaling is the most significant pathway leading to EMT, cancer metastases, and fibrosis, we also analyzed the effect of SIRT1 levels on the TGF-β pathway. The expression of downstream genes involved in the TGF-β pathway was significantly increased in the absence of SIRT1 from kidney tubules after injury, as confirmed by quantitative RT-PCR expression of TGF-β pathway downstream targets Ptx2, Lefty, and Afp (Figure 3D). However, there was no significant change in TGF-β expression itself among all groups subjected to kidney injury (Figure 3D).

To address whether the SIRT1 regulation of MMP7 expression was via the TGF-β pathway, we first monitored MMP7 expression in HK-2 kidney epithelial cells that either overexpressed or had knocked down levels of SIRT1 (Figure S2A). Overexpression of SIRT1 reduced the levels of TGF-β-induced MMP7, while knockdown of SIRT1 increased levels (Figure 3F). To confirm that SIRT1 regulated MMP7 via TGF-β signaling, we next constructed a luciferase reporter driven by a large fragment of MMP7 upstream DNA (−660 to −216) and tested it in wild-type, SIRT1+/−, and SIRT1-overexpressing mouse embryonic fibroblasts (MEFs). This reporter showed a strong regulation by SIRT1, which was partially normalized by small hairpin RNA (shRNA) to Smad4, the transcription factor that responds to TGF-β signaling (Figures 3E and S3B).

The SIRT1 effects on TGF-β and MMP7 might occur via an interaction between the TGF-β-activated transcription factor Smad4 and a site in the MMP7 promoter. To test this idea, we performed chromatin immunoprecipitation assay, which revealed a direct interaction of Smad4, with a specific region of MMP7 promoter (−438 to −379, but not with other promoter regions (Figures 3G and S3C). Critically, this interaction is greatly enhanced in the SIRT1−/− kidneys and reduced in kidneys overexpressing SIRT1. To further validate the relevance of this MMP7 promoter site, we constructed a luciferase reporter with only the −438 to −379 region and tested it in MEFs. Luciferase levels were activated by TGF-β, and activation was higher in SIRT1−/− MEFs and blunted in SIRT1+/-overexpressing MEFs (Figure 3H). The increase in activity of this promoter in SIRT1−/− MEFs was eliminated by treating cells with shRNA for Smad4.

We confirmed the interaction between Smad4 and the MMP7 promoter by chromatin immunoprecipitation in HMLER T1KD cells (Figure 3I). There was no direct interaction of SIRT1 and the MMP7 promoter in HMLER cells (Figure 3I), suggesting SIRT1 may function by deacetylating Smad4. We also used a different assay for Smad4 activity—a Gal4 fusion to a Smad2/4 interacting motif from Fox H1 to recruit phosphorylated Smad2-Smad4 complexes to a Gal4 binding site that drives luciferase (Ross et al., 2006). Using this assay in the MEFs, there was again more activation of Smad2-Smad4 complex in the absence of SIRT1 and less activation in cells overexpressing SIRT1 (Figures S3D and S3E).

To test whether SIRT1 deacetylates Smad4, we immunoprecipitated Smad4 and also Smad2 from mouse kidneys and probed western blots with antibodies to the Smad proteins or acetyl lysine (Figure 4A). This experiment showed a clear increase in acetylation of Smad4 but not Smad2 in the KSKO kidneys. To investigate the effect of aging on the Smad4 pathway in wild-type kidneys, we tested the levels of SIRT1 protein and Smad4 acetylation in kidneys at different ages. Interestingly, there was a decrease in SIRT1 levels in kidneys from 2-year-old mice as compared to young mice at 3 months of age (Figure 4B). Moreover, there was a corresponding increase in Smad4 acetylation in aged kidneys (Figure 4B). We also observed an increase in acetylation of Smad4 in SIRT1 KD HMLER cells (Figure 4C). Finally, SIRT1 and Smad4 were shown to interact at endogenous level in HMLER cells by chromatin immunoprecipitation (Figure S3F).

Furthermore, MMP7 protein levels were elevated in SIRT1 KD HMLER cells (Figure 4D). Since MMP7 cleaves E-cadherin from the cell surface (Noë et al., 2001; Zheng et al., 2009), we tested the effect of SIRT1 on E-cadherin in HMLER cells. SIRT1 KD HMLER cells showed modestly less E-cadherin on western blot analysis. This effect was blunted by the reduction of MMP7 levels suggesting that SIRT1 KD exerts its effect on E-cadherin via MMP7 (Figure 4D). Notably, TGF-β reduced E-cadherin in both, wild-type and SIRT1 KD HMLER cells, but to a much greater extent in SIRT1 KD cells, and this too was blunted by shRNA for MMP7 (Figure 4D).

β-catenin is associated with the E-cadherin cytoplasmic tail, and loss of E-cadherin leads to translocation of β-catenin from adheren junctions to the nucleus (Onder et al., 2008). As SIRT1 KD reduces E-cadherin levels in HMLER cells, we investigated whether this induced a change in the cellular localization of β-catenin upon TGF-β addition. Indeed, SIRT1 KD led to translocation of β-catenin from the cell junctions (characteristic of epithelial cells) to nuclei (characteristic of mesenchymal cells, Kalluri and Weinberg, 2009) upon addition of TGF-β (Figures 4E and S4).
Finally, we do not believe that the effect of SIRT1 on metastasis occurs via p53. HMLER cells are transfected with SV40, and the expressed T antigen is known to inactivate p53. Indeed, doxycycline was not able to induce p21, a p53 target, in HMLER cells, while serving as a potent inducer in 143b control cells (Figure S5).

**DISCUSSION**

Our results show that reduction of SIRT1 promotes metastasis of breast epithelial cells in an orthotopic model of breast cancer and promotes EMT and cell motility in these cells in vitro. Further, EMT could be induced in both breast epithelial and kidney epithelial cells in vitro, and this was also repressed by SIRT1. These effects were associated with the hyperactivation of TGF-β and hyperacetylation of Smad4 in the absence of SIRT1, leading to an increase in expression of MMP7, which we demonstrate is a Smad4 target. We suggest that the absence of SIRT1 leads to MMP7 hyperexpression and degradation of E-cadherin from the cell surface, thereby releasing β-catenin from the cadherin junctions to the nucleus, which is the characteristic of mesenchymal cells (Figures 5A and 5B).

The literature suggests that the role of SIRT1 in cancer may depend on the tumor type. SIRT1 has been shown to protect against gut carcinomas in APCmin mice (Firestein et al., 2008), as well as tumorigenesis in p53−/− mice (Wang et al., 2008; Vaziri et al., 2001). However, SIRT1 was associated with malignancy in prostate cancer and chronic myelogenous leukemia (Byles et al.,...
In prostate cancer, SIRT1 enhanced cell migration and metastasis after PC3 cancer cell tail injections by cooperating with EMT transcription factor ZEB1 to suppress E-cadherin transcription (Byles et al., 2012). The SIRT1 activator compound 1720 was shown to increase lung metastasis of implanted breast cancer cells, but EMT as a possible mechanism was not addressed (Suzuki et al., 2012). In normal mouse mammary epithelial cells, miR-200a negatively regulated SIRT1 expression and reduced EMT (Edes et al., 2011). However, an opposite role in cancer metastasis was indicated by the demonstration that miR-520c and miR-373 suppressed SIRT1 translation leading to increased expression of MMP9 and enhanced cell migration of fibrosarcoma cells (Liu and Wilson, 2012). To further confirm our data in animal studies, we performed the meta-analysis of human breast cancer trials and have shown that SIRT1 is downregulated in human invasive breast cancers.

Because of these seemingly conflicting data on SIRT1 in cancer, we employed a radically different model to follow up the cancer studies—fibrosis following kidney injury. Renal fibrosis after injury was mitigated in mice overexpressing SIRT1 in the kidney tubular epithelium and exacerbated in mice with SIRT1 knocked out in those cells. This repression of fibrosis was due to repression of TGF-β signaling. For years it was believed that EMT is a major mechanism of renal fibrosis. However, a more recent study using fate tracing showed that epithelial cells can give rise to interstitial myofibroblasts in wild-type mice following injury (Humphreys et al., 2010). We were able to confirm that EMT did not occur in fibrotic tissue of wild-type animals after injury. However, in the absence of SIRT1, 36% of interstitial myofibroblasts expressed the epithelial marker Hoxb7Cre, suggesting their epithelial origin.

In conclusion, SIRT1 reduces EMT in cancer and fibrosis, which lowers the expression of target genes.

**EXPERIMENTAL PROCEDURES**

**Mouse Strains**

Severe combined immunodeficiency mice were purchased from Charles River Laboratories. All other mice were in congenic C57Bl/6 background. KSKO mice were generated by crossing SIRT1 allele containing a floxed exon 4 (Cheng et al., 2003) with Cre-expressing mice driven by the kidney epithelial collecting tubule-specific Hoxb7Cre promoter (Jackson Laboratory). KSTG mice were generated by crossing SIRT1 loxP-flanked mice (Frestinet al., 2008) with mice having Hoxb7Cre promoter. Ctrl Tg mice had no loxP locus.
nor cre recombinase. All mice were housed at 25°C and 12:12 hr light/dark cycle. All experiments were performed in accordance to Massachusetts Institute of Technology guidelines and regulations and were approved by Committee on Animal Care.

**Cells and Treatment**

Immortalized tumorigenic primary human breast epithelial cells, HMLER cells (courtesy by R.A. Weinberg, Whitehead Institute), were maintained as described (Elenbaas et al., 2001). The SIRT1+/+ and SIRT1−/− MEFs have been described (Lin et al., 2009). HK-2 cells were from ATCC. Cells were treated with 5 ng/ml TGF-β (Invitrogen) or aristochatic acid (Sigma) every other day for 2–8 days (Yang et al., 2010; Yu et al., 2002).

**Plasmids and Cell Transfections**

Stable cells were generated using lentivirus or retrovirus. The plasmids expressing mSIRT1 and PRRL-GFP vectors were purchased from Addgene, Smad4-shRNA, and pSM2 vector from Open Biosystems. siRNA-SIRT1 plasmid has been previously described (Picard et al., 2004). Lentiviral vectors were made by pcr subcloning cDNA and ligating into pENTR-D-TOPO (Invitrogen), pENTR-D-TOPO vectors were sequenced and then the cDNA was transferred to pLenti-TO-VS-DEST (Invitrogen) through recombination. Cells were then virally infected. Transient transfections were performed by using Fugene transfection reagent (Roche).

**In Vivo Tumorigenesis and Metastasis Model**

Severe combined immunodeficiency (SCID) mice (Charles River Laboratories) were used in these studies, and all the protocols were approved by the Massachusetts Institute of Technology Committee on Animal Care. Mice were anesthetized with isoflurane. Five million cells in PBS, diluted 1:2 with Matrigel (Beckton Dickinson), were injected into one mammary gland per female (Onder et al., 2008). Animals were sacrificed 7.5 or 8 weeks postinjection (depending when the primary tumors reached 2 cm in diameter), or sooner if they became moribund.

**Acute Kidney Injury Model**

Four-month-old mice (n = 12 per group) were subjected to ischemia-reperfusion model of AKI by clamping both renal pedicles for 30 min with vascular clips (Roboz) (Yang et al., 2010). Blood was collected throughout the experiment and kidneys at the end. Mice were sacrificed 6 days and 6 weeks following the AKI and experiment was repeated twice.

**Flow Cytometric Analysis and Sorting**

Cell suspension from kidneys of control mice with cre-recombinase and KSKO mice after 4 days of treatment with TGF-β 100 μg/kg/day was prepared as described in Kitamoto et al. (2009). Following erythrocyt lysis, cells were resuspended in FACS buffer. Kidney cells were labeled using anti-α-SMA and anti-cre-recombinase primary antibodies and Alexa Fluor 488 and Alexa Fluor 647 secondary antibodies, counted by a FACScanCalibur Flow Cytometer (BD Biosciences) and analyzed using FlowJo software (Ashland, OR). α-SMA-positive cells were sorted using FACSAnia I (BD Biosciences).

**RNA Isolation and Analysis**

Total RNA from mouse kidneys and HMLER cells was isolated by using Trizol (QLAENG). cDNA was synthesized from total RNA by SuperScript III reverse transcriptase (Invitrogen) with random primers. The cDNA was then subjected to real-time quantitative RT-PCR analysis with gene-specific primers in the presence of CYBR green (Bio-Rad). Relative abundance of mRNA was normalized to rp19.

**Chromatin Immunoprecipitation Analysis**

Chromatin immunoprecipitation analysis from kidneys and HMLER cells was performed with Magna Chip kit (Millipore) by using Smad4 antibody (Abcam) and immunoglobulin (Ig) G. The primer sequences are in Table S2.

**Luciferase Assay**

Transcription of Smad2-Smad4 was detected by transfecting MEFs with FM-SIM plasmid comprising of Smad-interacting motif (SIM) and Fast/FoxH1 motif (FM), which interacts with phospho-Smad2, fused to the GaIl DNA-binding domain (Figure S5A) (Ross et al., 2006; courtesy of C. Hill, Cancer Research, UK). The MMP7 promoter region responsive to Smad4 (−438 to −379) and a larger DNA promoter fragment (−660 to −216) were cloned into pGL3-basic vector luciferase plasmid (Addgene) by using Sca1 and Xhol restriction endonucleases (New England BioLabs). Cells were cotransfected with MMP7 promoter-luciferase reporter and pRL-TK (Renilla luciferase; Promega) and treated with TGF-β 2 ng/ml for 48 hr. Luciferase activity was measured by Dual-Luciferase Reporter Assay System (Promega). The firefly luciferase activity was normalized to Renilla. The experiments were performed in triplicates and were repeated three times.
Statistical Analysis
The analyses were performed using ANOVA Dunnett test, except for survival, where log-rank test was used. Differences were considered significant if p < 0.05.

SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.cellrep.2013.03.019.

ACKNOWLEDGMENTS
We are grateful to Caroline Hill for FM-SIM plasmid and Robert A. Weinberg for HMLER cell line. We wish to thank Benjamin Humphreys for advice and helpful discussions. This work is supported by Fulbright Association postdoctoral fellowship to P.S., American Cancer Society, Grant Number; PF-11-258-1-TBG to E.O.W., F32 CA 132358 to E.L.B., Ellison/AFAR postdoctoral research grant to M.B. and grants from the NIH and a gift from the Glenn Medical Foundation to L.G. L.G. is co-chair of the Senior Advisory Board for Sirtris/GSK.

Received: June 1, 2012
Revised: January 5, 2013
Accepted: March 14, 2013
Published: April 11, 2013

REFERENCES


